Foley Hoag Represents Alcyone Therapeutics in Closing $23M in Funding

July 2, 2021

Foley Hoag LLP advised Alcyone Therapeutics, a Lowell, Massachusetts-based biotechnology company pioneering next-generation precision central nervous system (CNS) therapies, in closing $23 million in funding from funds affiliated with RTW Investments, LP.

Alcyone's precision CNS delivery technology platform allows for unprecedented control and versatility for biodistribution of genetic medicines to CNS regions of interest, including deep brain regions and spare off-target areas. Alcyone's CNS precision delivery can improve the efficiency of CNS gene therapy significantly impacting safety and efficacy, and the number of vectors needed, for an effective gene therapy.

Foley Hoag attorneys Patrick Connolly, Jeffrey Quillen, Jennifer Audeh, Brendan Burke, Sarah Ropiak and Kimberly Cyrus represented Alcyone in the transaction.

About Foley Hoag LLP

Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.